Nizax
76963-41-2CN/C(=C\[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1SGXXNSQHWDMGGP-IZZDOVSWSA-NNizatidine is a member of the class of 1,3-thiazoles having a dimethylaminomethyl substituent at position 2 and an alkylthiomethyl moiety at position 4. It has a role as a H2-receptor antagonist, a cholinergic drug and an anti-ulcer drug. It is an organic sulfide, a carboxamidine, a C-nitro compound, a member of 1,3-thiazoles and a tertiary amino compound.
Pharmaceuticals -> Gastric and Ulcer Drugs
Pharmaceuticals -> Listed in ZINC15
10-33mg/mL
3.86e-02 g/L
>49.7 [ug/mL] (The mean of the results at pH 7.4)
130-132 °C
203 °C
168.4 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]
168 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
169.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.
Nizatidine competes with histamine for binding at the H<sub>2</sub>-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.
Hepatic. Less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose).
Rapid (bioavailability of nizatidine exceeds 70%)
0.8 to 1.5 L/kg
40-60 L/h
76963-41-2CHEBI:7601化学的特性White Crystalline Powder
用途ヒスタミンH2 受容体遮断剤 です。胃粘膜のヒスタミンH2受容体を遮断し、 胃酸分泌を抑制作用を示します。
説明Nizatidine is the fifth H2-antagonist introduced to the world market as an antiulcer agent. It is reported to be effective in the treatment of both duodenal and gastric ulcers or the prevention of their recurrences. Given once-daily, nizatidine’s bioavailability is not diminished by the concurrent administration of an antacid.
使用Nizatidine is used for treating stomach and duodenum ulcers and other conditions accompanied by elevated acidity of the gastrointestinal tract.
一般的な説明Nizatidine, N-[2-[[[2-(dimethylamino)methyl]-4-thiazolyl]methyl]thio]-ethyl]-N'-methyl-2-nitro-1,1-ethenediamine (Axid), is an off-white to buff crystallinesolid that is soluble in water, alcohol, and chloroform. It isa thaizole derivative of raniditine and has pKas of 2.1 (side chain) and 6.8 (dimethylamino). Nizatidine’s mechanism ofaction is similar to other H2-antagonists, as is its receptor selectivity.It is more potent than cimetidine.Nizatidine has excellent oral bioavailability (>90%).The effects of antacids or food on its bioavailability arenot clinically significant. The elimination half-life is 1 to2 hours. It is excreted primarily in the urine (90%) andmostly as unchanged drug (60%). Metabolites include nizatidinesulfoxide (6%), N-desmethylnizatidine (7%), andnizatidine N-oxide (dimethylaminomethyl function).Nizatidine has no demonstrable antiandrogenic action, effectson other hormones, or inhibitory effects on cytochromeisozymes involved in the metabolism of other drugs.
定義ChEBI: A member of the class of 1,3-thiazoles having a dimethylaminomethyl substituent at position 2 and an alkylthiomethyl moiety at position 4.